| Patents for A61K 49 - Preparations for testing in vivo (35,376) |
|---|
| 09/18/2003 | US20030175807 Chimeric GFP-aequorin as bioluminescent Ca+at the single cell level |
| 09/18/2003 | US20030175766 Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
| 09/18/2003 | US20030175741 PCP-administered (phencyclidine/angel dust) chronic animal models; drug screening |
| 09/18/2003 | US20030175289 TIE ligands |
| 09/18/2003 | US20030175211 Phospholipid stabilized microbubbles filled with air, nitrogen or perfluoropropane, for ultrasound imaging, image the inside of blood- stream vessels and cavities of living beings |
| 09/18/2003 | US20030175209 Image diagnosis of a brain tumor, renal carcinoma; tumor treatment therapies, immunotherapy |
| 09/18/2003 | US20030175208 Treating a cancer of the immune system |
| 09/18/2003 | US20030175205 Comprising a radioactive materials for detecting and/or quantifying diseases or conditions associated with cancer, infections, inflammation; a 2-propane carboxylic ester with a attached phosphatidic acid group |
| 09/18/2003 | US20030173541 Colloidal nanocrystals with high photoluminescence quantum yields and methods of preparing the same |
| 09/18/2003 | CA2813780A1 Genetic products differentially expressed in tumors and use thereof |
| 09/18/2003 | CA2478924A1 Cancer associated araf1 protein kinase and its uses |
| 09/18/2003 | CA2478120A1 Contrast agents containing ferritin for magnetic resonance imaging and methods related thereto |
| 09/18/2003 | CA2478083A1 Biospecific contrast agents |
| 09/18/2003 | CA2478082A1 Uses of monoclonal antibody 8h9 |
| 09/18/2003 | CA2477614A1 Biomarker for efficacy of appetite suppressant drugs |
| 09/17/2003 | EP1345039A1 Magnetic resonance arteriography with dynamic, intravenous injection of a contrast agent |
| 09/17/2003 | EP1343770A2 Lithium complexes of n-(1-hydroxymethyl-2,3-dihydroxypropyl)-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane, production and use thereof |
| 09/17/2003 | EP1343758A1 Substituted bis-indole derivatives useful as contrast agents, pharmaceutical compositions containing them and intermediates for producing them |
| 09/17/2003 | EP1343524A1 Vaccine based on a cellular penetration factor from an apicomplexan parasite |
| 09/17/2003 | EP1343367A2 Non-human animal disease models |
| 09/17/2003 | EP0959906B1 Delta 1,6 bicyclo [4,4,0] functional dyes for contrast enhancement in optical imaging |
| 09/17/2003 | EP0804439B1 Beta, beta '-dihydroxy meso-substituted chlorins, isobacteriochlorins, bacteriochlorins, and methods for making the same from beta ,beta '-unsubstituted tetrapyrrolic macrocycles |
| 09/16/2003 | US6620404 Gaseous ultrasound contrast media and method for selecting gases for use as ultrasound contrast media |
| 09/16/2003 | US6620403 In vivo chemosensitivity screen for human tumors |
| 09/16/2003 | CA2068089C Method and compositions for using non-ionic contrast agents to reduce the risk of clot formulation in diagnostic procedures |
| 09/12/2003 | WO2003075003A1 Therapeutic properties of oils |
| 09/12/2003 | WO2003074523A2 Gadolinium chelate oligomers, their use as contrast products in magnetic resonance imaging and their synthesis intermediates |
| 09/12/2003 | WO2003074519A1 Coumarines useful as biomarkers |
| 09/12/2003 | WO2003074091A2 Near infrared fluorescent contrast agent and method for fluorescence imaging |
| 09/12/2003 | WO2003074005A2 Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy |
| 09/12/2003 | WO2003026401A3 Kv3.3b POTASSIUM CHANNEL DISRUPTIONS, COMPOSITIONS AND METHODS RELATED THERETO |
| 09/12/2003 | WO2003020701A9 Multi-use multimodal imaging chelates |
| 09/12/2003 | WO2002082041A3 Production and use of novel peptide-based agents for use with bi-specific antibodies |
| 09/12/2003 | WO2002072830A3 Proteins associated with cell growth, differentiation, and death |
| 09/12/2003 | CA2666005A1 Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy |
| 09/12/2003 | CA2478272A1 Near infrared fluorescent contrast agent and method for fluorescence imaging |
| 09/12/2003 | CA2477836A1 Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy |
| 09/12/2003 | CA2477738A1 Therapeutic properties of oils |
| 09/12/2003 | CA2472298A1 Coumarines useful as biomarkers |
| 09/11/2003 | US20030171687 Reagent and method for measuring lung function |
| 09/11/2003 | US20030171561 Aminocarboxylate ligands having substituted aromatic amide moieties |
| 09/11/2003 | US20030171438 Method for treatment of external secretion disorders |
| 09/11/2003 | US20030170889 In vivo assay for anti angiogenic compounds |
| 09/11/2003 | US20030170743 Determination sensitivity; administering gene moderators |
| 09/11/2003 | US20030170297 Lipid-based drug delivery systems containing phospholipase a2 degradable lipid derivatives for topical application to the skin |
| 09/11/2003 | US20030170179 As contrast medium for fluorescence and transillumination diagnostics; drugs |
| 09/11/2003 | US20030170177 Useful as vehicle for gene therapy, and in imaging |
| 09/11/2003 | US20030170174 For therapy of diseases, such as parasitic and viral infections, conditions associated with inflammation and infection, and conditions mediated by cell-proliferation or collagen formation; contrast agents |
| 09/11/2003 | US20030170173 Contrast agents |
| 09/10/2003 | EP1341921A2 Hydrolases |
| 09/10/2003 | EP1341559A2 Radioactive seed with multiple markers and method for using same |
| 09/10/2003 | EP1341558A2 A novel system for the evaluation of the activity and/or specificity of a viral component |
| 09/10/2003 | EP1341557A2 Non-isotopic detection of osteoblastic activity in vivo using modified bisphosphonates |
| 09/10/2003 | EP1341521A2 Nanoparticulate compositions comprising a drug and copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers |
| 09/10/2003 | EP1150943B1 Preparation of iodixanol |
| 09/10/2003 | EP0993306B1 Perfluoroalkylated oligomer compounds, process for preparing the same and their use in nmr diagnosis |
| 09/10/2003 | EP0946202B1 Contrast agents |
| 09/10/2003 | EP0873139B1 Biotinylated antibodies with reduced net positive charge and toxin, drug or chelate |
| 09/10/2003 | CN1440816A Improvement for diagnosis and/or therapeutic agnet and its relative improvement |
| 09/10/2003 | CN1440815A Ingredient and production process of Chinese medicinal digestive tract contrast medium |
| 09/10/2003 | CN1120695C Ultrasonic spectral contrast imaging |
| 09/09/2003 | US6616912 Semipermeable membrane for use in evaluating activity of anticarcinogenic agents on cells |
| 09/09/2003 | CA2062105C Purified mite allergen |
| 09/04/2003 | WO2003072755A2 Transgenic zebrafish models for thrombosis |
| 09/04/2003 | WO2003072608A1 Anti-human tenascin monoclonal antibody |
| 09/04/2003 | WO2003072560A1 Triiodine aromatics containing perfluoroalkyl groups and forming micelles, method for their production and their use as contrast media |
| 09/04/2003 | WO2003072558A2 Arylsulfone derivatives |
| 09/04/2003 | WO2003072548A1 Pyridyl sulfone derivatives as 5-ht receptor antagonists |
| 09/04/2003 | WO2003072144A1 Use of 13c labelled substance for measuring lung function |
| 09/04/2003 | WO2003072125A1 Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides |
| 09/04/2003 | WO2003071953A1 Photodynamic diagnosis of oral cancer |
| 09/04/2003 | WO2003064451A3 MODULATION OF TYPE IIβ PHOSPHOINOSITIDE PHOSPHATE KINASE |
| 09/04/2003 | WO2003028446A3 An invertebrate animal model with alzheimer-like pathology for screening and testing molecules |
| 09/04/2003 | WO2003012724A9 System and method for quantitative assessment of joint diseases and the change over time of joint diseases |
| 09/04/2003 | WO2002064062A8 Vertebroplasty injection device and bone cement therefor |
| 09/04/2003 | WO2002060919A3 Molecules with extended half-lives, compositions and uses thereof |
| 09/04/2003 | WO2002055742A3 Rapid method for screening compounds for in vivo activity |
| 09/04/2003 | WO2002020769A9 Human and mouse targeting peptides identified by phage display |
| 09/04/2003 | US20030167474 Superoxide dismutase reduced animal model; Parkinson's disease, sepsis, amyotropic lateral sclerosis; prevent free radical damage |
| 09/04/2003 | US20030167006 Ultrasound contrast using halogenated xanthenes |
| 09/04/2003 | US20030166864 Controlling immunology; antiinflammatory agents |
| 09/04/2003 | US20030166838 A biologically active peptide at least 85% identical to a peptide: (a) X01ValSerGluX02GlnLeuX03HisX04X05GlyLysX06; (b) fragments containing amino acids 1-9, 1-10, 1-11, 1-12,(c) a salt or (d) N- or C- derivatives |
| 09/04/2003 | US20030166713 Photodynamid therapy |
| 09/04/2003 | US20030166560 Snail/mollusc polypeptides; anticonvulsant drug screening |
| 09/04/2003 | US20030166503 Method for recognizing and determining GnRH receptors and use of GnRH agonist for decreasing the replication of malignant cells bearing GnRH receptors of tumors orginating in the nervous system and/or meninges and/or of Kaposi sarcoma |
| 09/04/2003 | US20030166487 Normally liquid, omega-hydrofluoroalkyl ether compounds (and selected mixtures thereof) have a saturated perfluoroaliphatic chain of carbon atoms interrupted by one or more ether oxygen atoms. The compounds can be prepared, by decarboxylation of |
| 09/04/2003 | US20030165807 Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors |
| 09/04/2003 | US20030165432 Versatile hydrophilic dyes |
| 09/04/2003 | US20030165431 Measuring variations using magnetic resonance signals |
| 09/04/2003 | US20030165428 Methods and compositions comprising monitoring devices |
| 09/04/2003 | CA2477624A1 Transgenic zebrafish models for thrombosis |
| 09/04/2003 | CA2476173A1 Arylsulfone derivatives |
| 09/04/2003 | CA2475596A1 Use of 13c labelled substance for measuring lung function |
| 09/03/2003 | EP1339834A2 Enzymes |
| 09/03/2003 | EP1339748A2 G-protein coupled receptors |
| 09/03/2003 | EP1339671A2 1,7 and 1,9-diarylpolymethine salts |
| 09/03/2003 | EP1339431A1 Improved oral delivery of peptides using enzyme-cleavable membrane translocators |
| 09/03/2003 | EP1339373A1 Use of moulding compounds for producing treatment devices |
| 09/03/2003 | EP1113822B1 Near infrared fluorescent contrast agent and fluorescence imaging |
| 09/03/2003 | EP1019021B1 Stabilized preparations for use in metered dose inhalers |